Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Coleman

Showing results (91-100 of 117) with videos related to

Pageof 12
Sort By:
Urologic Oncology|December 22, 2023
Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinomaStephen W Reese, Lennert Eismann, Charlie White, et al.
European Urology Focus|August 14, 2017
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial CarcinomaSumit Isharwal, François Audenet, Esther Drill, et al.
European Urology Oncology|November 19, 2019
The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive NephrectomyRenzo G DiNatale, Wanling Xie, Maria F Becerra, et al.
Medrxiv : the Preprint Server for Health Sciences|May 2, 2025
Pathologic Response to Immunotherapy is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell CarcinomaYash S Khandwala, Stephen W Reese, Burcin A Ucpinar, et al.
European Urology Oncology|November 27, 2025
Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell CarcinomaYash S Khandwala, Stephen W Reese, Burcin A Ucpinar, et al.
European Urology Focus|March 15, 2022
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell CarcinomasAngela Yoo, Cerise Tang, Mark Zucker, et al.
Cell Metabolism|July 6, 2023
Immunometabolic coevolution defines unique microenvironmental niches in ccRCCCerise Tang, Amy X Xie, Eric Minwei Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaJack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
JAMA Oncology|November 22, 2019
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney CancerSundeep Agrawal, Naomi B Haas, Mohammadhadi Bagheri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2021
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell CarcinomaKyrollis Attalla, Renzo G DiNatale, Phillip M Rappold, et al.
Pageof 12

Showing results (91-100 of 117) with videos related to

Sort By:
Pageof 12
Urologic Oncology|December 22, 2023
Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinomaStephen W Reese, Lennert Eismann, Charlie White, et al.
European Urology Focus|August 14, 2017
Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial CarcinomaSumit Isharwal, François Audenet, Esther Drill, et al.
European Urology Oncology|November 19, 2019
The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive NephrectomyRenzo G DiNatale, Wanling Xie, Maria F Becerra, et al.
Medrxiv : the Preprint Server for Health Sciences|May 2, 2025
Pathologic Response to Immunotherapy is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell CarcinomaYash S Khandwala, Stephen W Reese, Burcin A Ucpinar, et al.
European Urology Oncology|November 27, 2025
Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell CarcinomaYash S Khandwala, Stephen W Reese, Burcin A Ucpinar, et al.
European Urology Focus|March 15, 2022
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell CarcinomasAngela Yoo, Cerise Tang, Mark Zucker, et al.
Cell Metabolism|July 6, 2023
Immunometabolic coevolution defines unique microenvironmental niches in ccRCCCerise Tang, Amy X Xie, Eric Minwei Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2021
Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell CarcinomaJack P Gleeson, Ines Nikolovski, Renzo Dinatale, et al.
JAMA Oncology|November 22, 2019
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney CancerSundeep Agrawal, Naomi B Haas, Mohammadhadi Bagheri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2021
Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell CarcinomaKyrollis Attalla, Renzo G DiNatale, Phillip M Rappold, et al.
Pageof 12